Back to search results

A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Non-muscle Invasive Bladder Cancer · Non-Muscle Invasive Bladder Urothelial Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Moffitt Cancer Center, Tampa, Florida, United States

    Contact: Study coordinator (Arfa Mustasam, MBBS, CCRP) · Arfa.Mustasam@moffitt.org · 813-745-7272
    Contact: Principal Investigator (Juskaran Chadha, DO)

  • Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

    Contact: Study coordinator (Alicia Alexander-Moore) · aca108@cinj.rutgers.edu · 732-235-9850
    Contact: Principal Investigator (Saum Ghodoussipour, MD)

  • Icahn School of Medicine at Mount Sinai, New York, New York, United States

    Contact: Study coordinator (Lindsay Diamond) · lindsay.diamond@mssm.edu
    Contact: Principal Investigator (John P Sfakianos, MD)

  • Weill Cornell Medical Center, New York, New York, United States

    Contact: Study coordinator (Amalia Korniyenko) · nak4026@med.cornell.edu · 646-962-9406
    Contact: Principal Investigator (Douglas Scherr, MD)
Study leads

  • John Sfakianos, MD

    Principal Investigator

    Icahn School of Medicine at Mount Sinai

View source on ClinicalTrials.gov(opens in a new tab)